Anogenital neoplasia in AIDS
- 1 September 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 16 (5) , 455-462
- https://doi.org/10.1097/00001622-200409000-00008
Abstract
We review the recent literature on anogenital neoplasms in AIDS, with emphasis on cancers associated with HPV infection. Immune reactivity to HPV as well as novel immunotherapeutic and preventative strategies are discussed. Many AIDS-associated neoplasms are associated with HPV infection. Whether cervical cancer is truly an AIDS-associated neoplasm has recently been questioned, while the association of anal cancer with AIDS in both males and females is more convincing. Recent reports cast doubt on the efficacy of HAART therapy for HPV-induced anogenital neoplasms, despite efficacy in improving disease caused by other infectious agents. We include here new data on humoral and cellular immune responses to HPV. VLP serology has been reported to be associated with outcome of cervical cancer. VLP seropositivity has been reported to be a favorable prognostic sign in women with HPV 16 positive cervical carcinoma. Several investigators have questioned the immunogenicity of the oncogenic HPV type 16 compared with other HPV types. It has recently been found that in HIV-infected patients, lymphoproliferative cellular immune responses (CMI) to HPV 16 peptides are not associated with CD4 counts, whereas responses to recall antigens and mitogens are associated with CD4 counts. CD4 + T cells may not be responsible for protective cellular immune responses to HPV. VLP serology and CMI responses may be the future intermediate surrogate biomarkers for HPV-associated anogenital neoplasia trials. Several new therapeutic vaccine strategies for management of HPV-induced neoplasia are reviewed. Most anogenital neoplasms occurring with increased frequency in patients with HIV/AIDS are associated with HPV infections. Current treatment strategies are not effective in clearing anogenital HPV infection and need improvement. Immunotherapy with novel vaccines will provide both prevention and therapy for these common malignancies.Keywords
This publication has 49 references indexed in Scilit:
- High-Risk Human Papillomavirus DetectionAmerican Journal of Clinical Pathology, 2004
- Immunogenicity against Human Papillomavirus Type 16 Virus-Like Particles Is Strongly Enhanced by the PhoPcPhenotype inSalmonella entericaSerovar TyphimuriumInfection and Immunity, 2004
- Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasiaGynecologic Oncology, 2004
- Screening und Therapie der analen intraepithelialen Neoplasie (AIN) und des Analkarzinoms bei HIV-InfektionDeutsche Medizinische Wochenschrift (1946), 2003
- Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatmentJournal of General Virology, 2003
- Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16Immunology & Cell Biology, 2003
- Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescentsAIDS, 2003
- Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I moleculesVaccine, 2002
- Enhanced Enzyme-Linked Immunosorbent Assay for Detection of Antibodies to Virus-Like Particles of Human PapillomavirusJournal of Clinical Microbiology, 2002
- Lower Genital Tract Intraepithelial Neoplasia in HIV-Infected WomenObstetrical & Gynecological Survey, 1999